BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29208369)

  • 1. Prophylactic 3-hour graduated infusion schedule minimizes risk of carboplatin hypersensitivity reactions - A prospective study.
    Koul A; Forsland EL; Bjurberg M
    Gynecol Oncol; 2018 Feb; 148(2):363-367. PubMed ID: 29208369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.
    O'Cearbhaill R; Zhou Q; Iasonos A; Hensley ML; Tew WP; Aghajanian C; Spriggs DR; Lichtman SM; Sabbatini PJ
    Gynecol Oncol; 2010 Mar; 116(3):326-31. PubMed ID: 19944454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.
    LaVigne K; Hyman DM; Zhou QC; Iasonos A; Tew WP; Aghajanian C; Makker V; Hensley ML; Konner J; Grisham RN; Cangemi N; Soldan K; Spriggs DR; Sabbatini PJ; OʼCearbhaill RE
    Int J Gynecol Cancer; 2018 Jul; 28(6):1176-1182. PubMed ID: 29757876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Prophylactic Extended-Infusion Carboplatin on Incidence of Hypersensitivity Reactions in Patients with Ovarian, Fallopian Tube, or Peritoneal Carcinomas.
    Pasternak AL; Link NA; Richardson CM; Rose PG
    Pharmacotherapy; 2016 Jul; 36(7):723-30. PubMed ID: 27196693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity.
    Rose PG; Fusco N; Smrekar M; Mossbruger K; Rodriguez M
    Gynecol Oncol; 2003 Jun; 89(3):429-33. PubMed ID: 12798707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity.
    Chung SJ; Kang SY; Kang RY; Kim YC; Lee KH; Kim TY; Han SW; Kang HR
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):777-785. PubMed ID: 30105458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin.
    Arimoto T; Oda K; Nakagawa S; Kawana K; Tsukazaki T; Adachi K; Matsumoto Y; Yano T; Kozuma S; Taketani Y
    J Obstet Gynaecol Res; 2013 Jan; 39(1):336-40. PubMed ID: 22690725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.
    Schwartz JR; Bandera C; Bradley A; Brard L; Legare R; Granai CO; Dizon DS
    Gynecol Oncol; 2007 Apr; 105(1):81-3. PubMed ID: 17157366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study.
    Takase N; Matsumoto K; Onoe T; Kitao A; Tanioka M; Kikukawa Y; Yamaguchi S; Fujiwara K; Negoro S
    Int J Clin Oncol; 2015 Jun; 20(3):566-73. PubMed ID: 25030546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.
    Altwerger G; Gressel GM; English DP; Nelson WK; Carusillo N; Silasi DA; Azodi M; Santin A; Schwartz PE; Ratner ES
    Gynecol Oncol; 2017 Jan; 144(1):77-82. PubMed ID: 27789084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Hypersensitivity Reactions to Carboplatin Retreatment in Gynecologic Cancer Patients between One and Two Hour Infusions: a Randomized Trial Study.
    Pornwattanakrilert W; Suprasert P
    Asian Pac J Cancer Prev; 2017 Feb; 18(2):425-430. PubMed ID: 28345825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Readministration of Platinum Agents in Recurrent Ovarian Cancer Patients Who Developed Hypersensitivity Reactions to Carboplatin.
    Narui C; Tanabe H; Shapiro JS; Nagayoshi Y; Maruta T; Inoue M; Hirata Y; Komazaki H; Takano H; Niimi S; Isonishi S; Okamoto A
    In Vivo; 2019; 33(6):2045-2050. PubMed ID: 31662536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
    Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
    Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies.
    Koshiba H; Hosokawa K; Kubo A; Miyagi Y; Oda T; Miyagi Y; Watanabe A; Honjo H
    Int J Gynecol Cancer; 2009 Apr; 19(3):460-5. PubMed ID: 19407575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin.
    Li Q; Cohn D; Waller A; Backes F; Copeland L; Fowler J; Salani R; O'Malley D
    Gynecol Oncol; 2014 Oct; 135(1):90-4. PubMed ID: 25110329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
    Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
    Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The retreatment of carboplatin via high-dose intraperitoneal chemotherapy in patients with a history of a hypersensitivity reaction.
    Rettenmaier MA; Gray CM; Lopez KL; Bechtol KA; Goldstein BH
    Am J Obstet Gynecol; 2014 Feb; 210(2):e1-2. PubMed ID: 24184183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study.
    Gomez R; Harter P; Lück HJ; Traut A; Kommoss S; Kandel M; du Bois A
    Int J Gynecol Cancer; 2009 Oct; 19(7):1284-7. PubMed ID: 19823066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions.
    Kawarada Y; Miyazaki M; Itoh A; Araki R; Iwamizu H; Kataoka T; Kumakura Y; Ota A; Nagai T; Yamada K
    Int J Clin Oncol; 2017 Jun; 22(3):593-599. PubMed ID: 28124284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Successful desensitization protocol for patients with hypersensitivity reactions caused by carboplatin].
    Nishio S; Koyanagi T; Miyabe K; Kuromatsu H
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):731-3. PubMed ID: 20414037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.